Total Payments
$165,005
2024 Payments
$5,568
Companies
57
Transactions
697
Medicare Patients
5,945
Medicare Billing
$839,576
Payment Breakdown by Category
Consulting$87,457 (53.0%)
Other$36,713 (22.2%)
Education$16,811 (10.2%)
Food & Beverage$14,908 (9.0%)
Travel$9,116 (5.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $87,457 | 46 | 53.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $20,963 | 7 | 12.7% |
| Education | $16,811 | 3 | 10.2% |
| Long term medical supply or device loan | $15,750 | 3 | 9.5% |
| Food and Beverage | $14,908 | 604 | 9.0% |
| Travel and Lodging | $9,116 | 34 | 5.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Coala Life Inc | $48,073 | 25 | $0 (2022) |
| AngioDynamics, Inc. | $38,285 | 13 | $0 (2024) |
| CVRx, Inc. | $17,173 | 30 | $0 (2023) |
| BIOTRONIK INC. | $16,421 | 10 | $0 (2019) |
| Novo Nordisk Inc | $9,142 | 17 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $8,260 | 30 | $0 (2023) |
| Regeneron Healthcare Solutions, Inc. | $6,227 | 9 | $0 (2019) |
| Boston Scientific Corporation | $5,026 | 23 | $0 (2023) |
| Abbott Laboratories | $3,935 | 20 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,741 | 159 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $5,568 | 47 | AngioDynamics, Inc. ($4,500) |
| 2023 | $3,731 | 79 | Medtronic, Inc. ($1,339) |
| 2022 | $13,546 | 82 | AngioDynamics, Inc. ($10,000) |
| 2021 | $34,360 | 123 | Coala Life Inc ($22,000) |
| 2020 | $38,454 | 55 | Coala Life Inc ($26,000) |
| 2019 | $4,041 | 73 | BIOTRONIK INC. ($2,414) |
| 2018 | $43,674 | 108 | CVRx, Inc. ($15,844) |
| 2017 | $21,633 | 130 | BIOTRONIK INC. ($9,606) |
All Payment Transactions
697 individual payment records from CMS Open Payments — Page 1 of 28
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $19.92 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/17/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $18.89 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/14/2024 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $24.21 | General |
| Category: Diabetes | ||||||
| 11/13/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $11.30 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/12/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $26.31 | General |
| Category: Cardiology | ||||||
| 11/07/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $2.24 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/21/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $25.77 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/21/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $11.69 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/18/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $1.58 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/03/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $8.12 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/18/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $11.09 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/16/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $15.08 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/13/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $9.89 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 07/30/2024 | United Imaging Healthcare North America LLC | PET (Device) | Food and Beverage | Cash or cash equivalent | $23.09 | General |
| Category: Medical Imaging | ||||||
| 07/24/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $20.32 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/25/2024 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $23.71 | General |
| Category: Diabetes | ||||||
| 06/20/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Food and Beverage | In-kind items and services | $19.85 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/17/2024 | Lexicon Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $25.68 | General |
| 06/12/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $11.03 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 06/04/2024 | Penumbra, Inc. | Penumbra System (Device) | Food and Beverage | Cash or cash equivalent | $95.20 | General |
| Category: Neurointervention | ||||||
| 05/30/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $3.74 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 05/29/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $16.11 | General |
| Category: Cardiology | ||||||
| 05/23/2024 | Impulse Dynamics (USA) Inc. | Optimizer (Device), Optimizer | Food and Beverage | Cash or cash equivalent | $173.36 | General |
| Category: Cardiovascular Device | ||||||
| 05/08/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $14.83 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 04/24/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $18.67 | General |
| Category: Cardiology/Vascular Diseases | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 30 | 1,476 | 5,279 | $870,403 | $199,817 |
| 2022 | 31 | 1,638 | 3,227 | $855,336 | $203,295 |
| 2021 | 31 | 1,277 | 2,239 | $721,583 | $200,551 |
| 2020 | 40 | 1,554 | 5,081 | $812,479 | $235,913 |
Total Patients
5,945
Total Services
15,826
Medicare Billing
$839,576
Procedure Codes
138
All Medicare Procedures & Services
138 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 166 | 300 | $118,105 | $38,599 | 32.7% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2023 | 90 | 665 | $120,849 | $22,839 | 18.9% |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | Office | 2023 | 59 | 401 | $100,250 | $21,755 | 21.7% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 98 | 545 | $97,555 | $19,344 | 19.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 125 | 195 | $45,045 | $18,535 | 41.1% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 99 | 101 | $115,700 | $14,168 | 12.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 72 | 99 | $27,511 | $8,629 | 31.4% |
| 93229 | Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | Office | 2023 | 13 | 13 | $17,600 | $8,318 | 47.3% |
| 93297 | Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | Office | 2023 | 52 | 366 | $23,790 | $6,747 | 28.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 48 | 49 | $20,445 | $6,466 | 31.6% |
| 93925 | Ultrasound of leg arteries or artery grafts | Office | 2023 | 20 | 23 | $9,775 | $4,061 | 41.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 21 | 21 | $5,760 | $3,502 | 60.8% |
| 93970 | Ultrasound study of arm or leg veins with compression and maneuvers | Office | 2023 | 23 | 27 | $9,450 | $3,406 | 36.0% |
| 93460 | Insertion of tube in right and left heart chambers and coronary artery for diagnosis with review by radiologist | Facility | 2023 | 11 | 11 | $48,675 | $3,274 | 6.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 29 | 45 | $9,990 | $2,868 | 28.7% |
| 93296 | Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | Office | 2023 | 52 | 153 | $17,618 | $2,409 | 13.7% |
| 99458 | Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | Office | 2023 | 37 | 65 | $9,230 | $1,888 | 20.5% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2023 | 29 | 88 | $7,920 | $1,838 | 23.2% |
| 93295 | Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | Office | 2023 | 23 | 66 | $14,040 | $1,737 | 12.4% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 134 | 149 | $11,175 | $1,572 | 14.1% |
| 93290 | Evaluation of implantable heart and blood vessel monitoring system | Office | 2023 | 35 | 43 | $3,023 | $1,273 | 42.1% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 25 | 25 | $7,500 | $1,216 | 16.2% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 23 | 23 | $9,200 | $1,197 | 13.0% |
| 93280 | Programming of dual lead pacemaker system | Office | 2023 | 18 | 23 | $3,330 | $1,195 | 35.9% |
| 93283 | Programming of dual lead implantable defibrillator system | Office | 2023 | 14 | 14 | $2,648 | $937.51 | 35.4% |
About Dr. Gil Vardi, M.D
Dr. Gil Vardi, M.D is a Cardiovascular Disease healthcare provider based in Saint Louis, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1437173119.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gil Vardi, M.D has received a total of $165,005 in payments from pharmaceutical and medical device companies, with $5,568 received in 2024. These payments were reported across 697 transactions from 57 companies. The most common payment nature is "Consulting Fee" ($87,457).
As a Medicare-enrolled provider, Vardi has provided services to 5,945 Medicare beneficiaries, totaling 15,826 services with total Medicare billing of $839,576. Data is available for 4 years (2020–2023), covering 138 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Other Specialties Cardiovascular Disease, Interventional Cardiology
- Location Saint Louis, MO
- Active Since 07/27/2006
- Last Updated 12/06/2021
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1437173119
Products in Payments
- Coala Heart Monitor (Device) $48,073
- Auryon Laser System 100-120 Vac (Device) $25,750
- Barostim Neo System (Device) $17,173
- PRALUENT (Drug) $7,957
- Auryon (Device) $6,806
- PRALUENT ALIROCUMAB INJECTION (Biological) $6,193
- WATCHMAN (Device) $2,892
- VersaCross Access Solution (Device) $1,944
- ENTRESTO (Drug) $1,437
- Cardiac Mapping System (Device) $1,390
- MICRA (Device) $1,292
- Peripheral Orbital Atherectomy System (Device) $843.79
- Pacemakers (Device) $800.00
- CRT-Ds (Device) $578.15
- CRT Leads (Device) $546.00
- ELIQUIS (Drug) $486.30
- Mitra Clip system (Device) $481.65
- LifeVest (Device) $470.16
- CoreValve Evolut (Device) $413.20
- XARELTO (Drug) $358.49
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Saint Louis
Dr. Jasvindar Singh, Md, MD
Cardiovascular Disease — Payments: $883,337
Cardiovascular Disease $883,337
Dr. Harvey Serota, M.d, M.D
Cardiovascular Disease — Payments: $730,638
Cardiovascular Disease $730,638
Dr. Daniel Kelly, Md, MD
Cardiovascular Disease — Payments: $538,763
Cardiovascular Disease $538,763
Dr. Alan Zajarias, Md, MD
Cardiovascular Disease — Payments: $195,866
Cardiovascular Disease $195,866
Dr. George Kichura, M.d, M.D
Cardiovascular Disease — Payments: $194,189
Cardiovascular Disease $194,189
Dr. Anish Thomas, M.d, M.D
Cardiovascular Disease — Payments: $189,906
Cardiovascular Disease $189,906